Announcements Trials

Browse Landscape

Phase

Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Neoplasms 3 Ovarian Neoplasms 2 Breast Neoplasms 2 Triple Negative Breast Neoplasms 1 Solid Tumor, Unspecified, Adult 1 Solid Tumor 1 Prostatic Neoplasms 1 Metastatic Castration Resistant Prostate Cancer 1 Genital Neoplasms, Female 1 Fallopian Tube Neoplasms 1 Advanced Solid Tumors 1 Advanced Solid Tumor 1

Interventions

pembrolizumab 10 Docetaxel 8 senaparib 7 Injections 7 Capecitabine 7 Paclitaxel 6 Cisplatin 6 Irinotecan 5 Fluorouracil 5 Leucovorin 4 Cyclophosphamide 4 Bevacizumab 4 tislelizumab 3 pertuzumab 3 fludarabine 3 atezolizumab 3 Rifampin 3 Oxaliplatin 3 Itraconazole 3 Gemcitabine 3 ontuxizumab 2 navoximod 2 fluzoparib 2 durvalumab 2 Trastuzumab 2 Nivolumab 2 Midazolam 2 Hydroxychloroquine 2 Carboplatin 2 130-nm albumin-bound paclitaxel 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Solid Tumor × rucaparib × Clear all

NCT02986100 2023-06-09

AME

pharmaand GmbH

Phase 1 Completed

Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡